Alexion Pharmaceuticals, Inc. (ALXN) Shares Sold by Westpac Banking Corp
Westpac Banking Corp decreased its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 2.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,211 shares of the biopharmaceutical company’s stock after selling 463 shares during the quarter. Westpac Banking Corp’s holdings in Alexion Pharmaceuticals were worth $2,415,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in ALXN. Fiduciary Trust Co. acquired a new stake in shares of Alexion Pharmaceuticals in the second quarter valued at about $111,000. Huntington National Bank grew its position in shares of Alexion Pharmaceuticals by 1,084.6% in the second quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 987 shares during the period. Penserra Capital Management LLC grew its position in shares of Alexion Pharmaceuticals by 13.0% in the second quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 144 shares during the period. Acadian Asset Management LLC acquired a new stake in shares of Alexion Pharmaceuticals in the second quarter valued at about $160,000. Finally, Grove Bank & Trust grew its position in shares of Alexion Pharmaceuticals by 194.7% in the second quarter. Grove Bank & Trust now owns 1,347 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 890 shares during the period. Institutional investors and hedge funds own 94.60% of the company’s stock.
ALXN has been the topic of several research analyst reports. Zacks Investment Research lowered shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $165.00 target price on shares of Alexion Pharmaceuticals in a research report on Friday, July 14th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $170.00 target price on shares of Alexion Pharmaceuticals in a research report on Monday, October 23rd. Leerink Swann lifted their target price on shares of Alexion Pharmaceuticals from $136.00 to $170.00 and gave the company an “outperform” rating in a research report on Friday, July 28th. Finally, Morgan Stanley restated an “overweight” rating and set a $153.00 price target (up from $141.00) on shares of Alexion Pharmaceuticals in a research report on Friday, July 28th. Six investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the company. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $154.01.
Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at $115.94 on Tuesday. The stock has a market cap of $26,351.16, a P/E ratio of 24.12, a PEG ratio of 1.29 and a beta of 1.22. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $149.34. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.32 by $0.12. The business had revenue of $859.00 million for the quarter, compared to the consensus estimate of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The business’s revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.23 EPS. sell-side analysts anticipate that Alexion Pharmaceuticals, Inc. will post 4.81 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This article was first reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/11/07/alexion-pharmaceuticals-inc-alxn-shares-sold-by-westpac-banking-corp.html.
In related news, Director Ann M. Veneman sold 835 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the sale, the director now directly owns 5,480 shares of the company’s stock, valued at approximately $799,038.80. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Julie O’neill sold 11,160 shares of the company’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the sale, the executive vice president now directly owns 26,704 shares in the company, valued at $3,738,560. The disclosure for this sale can be found here. Insiders sold a total of 16,490 shares of company stock worth $2,337,251 over the last three months. Insiders own 4.35% of the company’s stock.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.